Mindmed enrolls first participant in a study of its session monitoring system

New york, jan. 18, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of mental health and addiction, today announced that it has enrolled the first subjects into its session monitoring system (sms-01) study evaluating the passive collection of sensory data during a consciousness-altering therapeutic session. sms-01 utilizes mindmed's session monitoring system (msms), which it believes could have therapeutic applications in the treatment of psychiatric disorders.
MNMD Ratings Summary
MNMD Quant Ranking